Impaired glucose tolerance and metformin: clinical and mechanistic aspects

Abstract

The Diabetes Prevention Program (DPP) showed that metformin reduced the incidence of diabetes in subjects with impaired glucose tolerance (IGT) who were at high risk of progression to type 2 diabetes. Metformin was not as efficient as intensive life style intervention, but had a clinically significant effect in obese individuals and in those with impaired fasting glucose (IFG). This review discusses the clinical implications and the mechanistic aspects of the effect of metformin in IGT and IFG. Acute actions of metformin on postprandial metabolism to improve hepatic glucose handling and improve the lipid profile could contribute to the lower incidence of diabetes. Longer term improvements in haemodynamic parameters and reduced oxidative stress are also implicated. Metformin offers a potential alternative or complement to lifestyle intervention for IGT, and deserves further evaluation in this respect.

Keywords

metformin impaired glucose tolerance postprandial fat metabolism oxidative stress.

Get full access to this article

View all access options for this article.

References

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

Bailey CJ The Diabetes Prevention Program: headline results. Br J Diabetes Vasc Dis 2001;1:62-4.

Turner RC , Holman RR , Stratton IM et al. UK Prospective Diabetes Study. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS 34) Lancet 1998;352:854-65.

Chan NN , Feher MD Metformin therapy in type 2 diabetes: beneficial effects beyond glucose-lowering . Curr Med Lit 2000;17:57-62.

Wiernsperger N. Metformin intrinsic vasculoprotective properties . Diabetes Technol Ther 2000;2:259-72.

Alberti Kgmm , Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus . Genève: World Health Organization , 1999.

Stern MP The insulin resistance syndrome in: Alberti KGMM , DeFronzo RA , Keen H , Zimmet P. International textbook of diabetes mellitus. Chichester : John Wiley & Sons. 1997;12:255-83.

Knowler WC , Narayan KM , Hanson RL et al. Preventing non-insulin-dependent diabetes. Diabetes 1995;44:483-8.

Valle T. , Tuomilehto J. , Eriksson J. Epidemiology of NIDDM in europids in: Alberti KGMM , DeFronzo RA , Keen H , Zimmet P. International textbook of diabetes mellitus. Chichester : John Wiley & Sons. 1997;7:125-42.

10.

De Courten M. , Bennett PH , Tuomilehto J. , Zimmet P. Epidemiology of NIDDM in non-europids in: Alberti KGMM , DeFronzo RA , Keen H , Zimmet P. International textbook of diabetes mellitus. Chichester : John Wiley & Sons. 1997;8:143-70.

11.

Dowse G. , Zimmet P. , Alberti Kgmm. Screening for diabetes and glucose intolerance in: Alberti KGMM , DeFronzo RA , Keen H , Zimmet P. International textbook of diabetes mellitus. Chichester : John Wiley & Sons 1997;89:1687-707.

12.

Donahue RP , Orchard TJ Diabetes mellitus and macrovascular complications: an epidemiological perspective . Diabetes Care 1992;15:1141-55.

13.

Peters AL , Davidson MB Aging and diabetes in: Alberti KGMM , DeFronzo RA , Keen H , Zimmet P. International textbook of diabetes mellitus. Chichester : John Wiley & Sons. 1997;58:1151-76.

14.

Diabetes Prevention Program Research Group. The diabetes prevention program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22;623-34.

15.

Diabetes Prevention Program Research Group. The diabetes prevention program. Baseline characteristics of the randomised cohort. Diabetes Care 2000;23:1619-29.

16.

Jarrett RJ , Keen H. , Fuller JH , McCartney M. Worsening to diabetes in men with impaired glucose tolerance (`borderline diabetes'). Diabetologia 1979;16:25-30.

17.

Hermann LS , Melander A. Biguanides: basic aspects and clinical uses in: International textbook of diabetes mellitus. London: John Wiley. 1997; 37:841-64.

18.

Cusi K. , DeFronzo RA Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89-131.

19.

Howlett HC , Bailey CJ A risk-benefit assessment of metformin in type 2 diabetes mellitus . Drug Safety 1999;20:489-503.

20.

Sartor G. , Scherstén B. , Carlström S. et al. Ten-year follow up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9.

21.

Keen H. , Jarrett RJ , McCartney P. The 10 year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 1982; 22:73-8.

22.

Li CL , Lu JM , Pan CY et al. Effect of metformin on patients with impaired glucose tolerance . Diabetic Med 1999;16:477-81.

23.

Morel Y. , Golay A. , Pernegert T. et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabetic Med 1999;16:650-5.

24.

Lehtovirta M. , Forsen B. , Gullstrom M. et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Med 2001; 18:578-83.

25.

Scheen AJ , Letiexhe MR , Lefebvre PJ Effects of metformin in obese patients with impaired glucose tolerance . Diabetes Metab Rev 1995;11: S69-S80.

26.

Ericsson KF , Lingärde F. Prevention of type 2 (non insulin dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991;34:891-8.

27.

Pan XR , Li GW , Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study Diabetes Care 1997;20:537-44.

28.

Tuomilehto J. , Lindström J. , Eriksson JG , Valle TT , Hämäläinen H. , Ilanne-Parikka P. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-50.

29.

Yang W. , Lin L. , Qi J. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab 2001;17:131-4.

30.

Scheen AJ Pharmacological prevention of the progression from impaired glucose tolerance towards type 2 diabetes: favourable effects of metformin and acarbose . Rev Med Liege 2001;56:727-30.

31.

Cuber JC , Bosshard A. , Vidal H. , Vega F. , Wiernsperger N. , Rapin JR Metabolic and drug distribution studies do not support direct inhibitory effects of metformin on intestinal glucose absorption. Diabete Metab 1994;20:532-9.

32.

Wiernsperger NF , Bailey CJ The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58(suppl 1):31-9.

33.

Fery F. , Plat L. , Balasse E. Effects of Metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism 1997;46:227-33.

34.

Yoa RG , Rapin JR , Wiernsperger NF , Martinaud A. , Belleville I. Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin. Clin Exp Pharmacol Physiol 1993;20:563-7.

35.

Yki-Järvinen H. The liver as a target for therapy in non-insulin dependent diabetes mellitus. Diab Nutr Metab 1991;7:109-19.

36.

Mevorach M. , Giacca A. , Aharon Y. , Hawkins M. , Shamoon H. , Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 1998;102;744-53.

37.

Ahrén B. , Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 2001;44:1998-2003.

38.

Kühl C. , Lindkaer Jensen S. , Vagn Nielsen O. , Pedersen J. The effect of dimethylbiguanide (DMB) on plasma insulin and glucagon concentrations in portal and peripheral venous blood. Diabetologia 1976;12:155.

39.

Wiernsperger NF Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab 1999; 25:110-27.

40.

Ohnhaus EE , Berger W. , Duckert F. , Oesch F. The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study. Klin Wochenschr 1983;61:851-7.

41.

Weintraub MS , Charach G. , Grosskopf I. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis 1998 ;141(suppl 1):S71-5.

42.

Paolisso G. , Howard BV Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 1998;15:360-6.

43.

Lefebvre PJ , Scheen AJ The postprandial state and risk of cardiovascular disease. Diabet Med 1998 ;15(suppl 4):S63-8.

44.

Jeppesen J. , Zhou MY , Chen YD , Reaven GM Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM . Diabetes Care 1994;17:1093-9.

45.

Balletshofer BN , Rittig K. , Enderle MK et al. Endothelial dysfunction is detectable in young normotensive first degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101:1780-4.

46.

Jaap AJ , Shore AC , Tooke JE Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997;40:238-43.

47.

Shah SA , Hafeez R. , Wilson MF et al. Resistance to vasodilatory effect of insulin in patients with non-insulin dependent diabetes mellitus (NIDDM) and patients with impaired glucose tolerance (IGT). Diabetologia 1995 ; 218:1946.

48.

Baron AD , Laakso M. , Brechtel G. , Hoit B. , Watt C. , Edelman SV Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in human obesity. J Clin Endocrinol Metab 1990;70:1525-33.

49.

Wiernsperger N.

Defects in microvascular haemodynamics during prediabetes: contributor or epiphenomenon?

Diabetologia 2000;43:1439-48.

50.

Williams SB , Goldfine AB , Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-701.

51.

Schinkovitz A. , Dittrich P. , Wascher TC Effects of a high-fat meal on resistance vessel reactivity and on indicators of oxidative stress in healthy volunteers. Clin Physiol 2001;21:404-10.

52.

Graier WF , Posch K. , Fleischhacker E. , Wascher TC , Kostner GM

Increased superoxide anion formation in endothelial cells during hyperglycemia: an adaptive response or initial Step of vascular dysfunction?

Diab Res Clin Pract 1999;45:153-60.

53.

Ceriello A. , Bortolotti N. , Motz E. et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999;48:1503-08.

54.

Plotnick GD , Corretti MC , Vogel RA Effect of antioxidant vitamins on the transient impairment of endothelium dependent brachial artery vasoactivity following a single high fat meal. JAMA 1997;278:1682-6.

55.

Gopaul NK , Manraj MD , Hébé A. et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001;44:706-12.

56.

Beisswenger PJ , Howell SK , O'Dell RM , Wood ME , Touchette AD , Szwergold BS A-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia . Diabetes Care 2001;24:726-32.

57.

Bertelsen M. , Änggard EE , Carrier MJ Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia 2001;44:605-13.

58.

Tirosh A. , Rudich A. , Potashnik R. , Bashan N. Oxidative stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes. Biochem J 2001;355:757-63.

59.

Tavridou A. , Unwin NC , Laker MF , White M. , Alberti Kgmm. Serum concentrations of vitamin A and E in impaired glucose tolerance. Clinica Chimica Acta 1997;266:129-40.

60.

Laight DW , Desai KM , Gopaul NK , Änggard EE , Carrier MJ Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br J Pharmacol 1999;128:269-71.

61.

Faure P. , Rossini E. , Wiernsperger N. , Richard MJ , Favier A. , Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999;48:353-7.

62.

Anurag P. , Anuradha CV Metformin improves lipid metabolism and attenuates lipid peroxidation in high fructose-fed rats. Diabetes, Obesity and Metabolism 2002;4:36-42.

63.

Singh S. , Melkani GC , Rani C. , Gaur SP , Agrawal V. , Agrawal CG Oxidative stress and metabolic control in non-insulin dependent diabetes mellitus . Indian J Biochem Biophys 1997;34:512-17.

64.

Ruggiero-Lopez D. , Lecomte M. , Moinet G. , Patereau G. , Lagarde M. , Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation . Biochem Pharmacol 1999;58:1765-73.

65.

Beisswenger PJ , Howell SK , Touchette AD , Lal S. , Szwergold BS Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198-202.

66.

Wiernsperger N. Vascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypotheses and facts . Diabetes Metab Rev 1994;10:287-307.

67.

Ellmerer M. , Hamilton-Wessler M. , Dea MK et al. Transentothelial transport defect in insulin resistant dogs. Diabetologia 2000;43(suppl 1):A155.

68.

Wascher TC , Wölkart G. , Russell JC , Brunner F. Delayed insulin transport across endothelium in insulin-resistant JCR:LA-cp rats. Diabetes 2000; 49:803-09.

69.

Cavaghan MK , Ehrmann DA , Polonsky KS Interactions between insulin resistance and insulin secretion in the development of glucose intolerance . J Clin Invest 2000;106(3):329-33.

70.

Bavenholm PN , Pigon J. , Ostenson CG , Efendic S. Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance . Diabetes 2001;50:1449-54.

71.

Weyer C. , Bogardus C. , Pratley RE Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999;48:2197-203.

72.

Patanè G. , Piro S. , Rabuazzo AM , Anello M. , Vigneri R. , Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose. Diabetes 2000;49:735-40.

73.

Lupi R. , Del Guerra S. , Fierabracci V. et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51(suppl 1):S134-7.

74.

Kwon G. , Xu G. , Marshall CA , McDaniel ML Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-delta 12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999;274:18702-08.

75.

Balks HJ , Krupp C. , Prank A. , Von Zur Mühlen A. Improvement of impaired regularity of pulsatile insulin secretion in patients with insulin resistance syndrome (IR) after Metformin (MF). Exp Clin Endocrinol Diabetes 1998; 106(suppl 1):V112.

76.

Zapecka-Dubno B. , Czyzyk A. , Dworak A. , Bak MI Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). Arzneim Forsch/Drug Res 1999;49:330-4.

77.

Boden G. Obesity, free fatty acids, and insulin resistance. Curr Opin Endocrinol Diabetes 2001;8:235-9.

78.

Beales PE , Giorgini A. , Annovazzi A. , Signore A. , Parlapiano C. , Pozzilli P. Metformin does not alter diabetes incidence in the NOD mouse. Horm Metab Res 1997;29:261-3.

79.

Schneider MB , Matsuzaki H. , Haorah J. et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120: 1263-70.

80.

Boden G. , Chen X. , Stein TP Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2001;280:E23-30.

81.

Stumvoll M. , Nurjhan N. , Periello G. , Dailey G. , Gerich JE Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.

82.

Pascot A. , Despres JP , Lemieux I. et al. Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation . Diabetes Care 2001;24:902-08.

83.

Porte D. Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci 1999;892:73-83.

84.

Björntorp P. , Rosmond R. Visceral obesity and diabetes. Drugs 1999;58 (suppl 1):13-18.

85.

Thomas CR , Turner SL , Jefferson WH , Bailey CJ Prevention of dexamethasone-induced insulin resistance by metformin . Biochem Pharmacol 1998;56:1145-50.

86.

Borst SE , Snellen HG , Lai HL Metformin treatment enhances insulin-stimulated glucose transport in skeletal muscle of Sprague-Dawley rats. Life Sciences 2000;67:165-74.

87.

Barret G. , Peyronnet J. , Grassi-Kassisse D. , Dalmaz Y. , Wiernsperger N. , Geloën A. Increased intraabdominal adipose tissue mass in fructose-fed rats: correction by metformin. Exp Clin Endocrinol Diab (in press).

88.

Banergi M. , Kurukulusuriya R. , Lebovitz HE Changes in body composition with Metformin (M) treatment: change in visceral fat linked to plasma triglyceride in African Americans (AA) with type 2 diabetes mellitus. Diabetes 2000;49(suppl 1):1309.

89.

Pasquali R. , Gambineri A. , Biscotti D. et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycistic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.

90.

Hadigan C. , Corcoran C. , Basgoz N. , Davis B. , Sax P. , Grinspoon S. Metformin in the treatment of HIV lipodystrophy Syndrome. A randomised controlled trial. JAMA 2000;284:472-7.